MedPath

Human Papillomavirus in Young People Epidemiological Research 4

Recruiting
Conditions
HPV Infection
Cancer
HPV 16 Infection
Human Papillomavirus Infection
HPV
Anal Cancer
Men
Registration Number
NCT05587738
Lead Sponsor
Monash University
Brief Summary

Anal cancer is overrepresented among gay, bisexual and other men who have sex with men (MSM), particularly those living with HIV. Australia was the first country to introduce a publicly funded national HPV vaccination program in 2007. This program was expanded to include schoolboys aged 12-13 years in 2013; with a 2-year catch-up for boys aged up to 15 years.

The goal of the HYPER4 study is to determine the prevalence of anal, genital and oral HPV among 500 young gay and bisexual men aged 21-25 years who were eligible for the school-based gender-neutral quadrivalent vaccination program.

Participants will be required to complete a questionnaire and provide samples for HPV testing. No follow-up visits will be required.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
Male
Target Recruitment
500
Inclusion Criteria
  • Men aged 21 to 25 years old in 2023-2024
  • Same-sex attracted
  • Residing in Australia since 2013
Exclusion Criteria
  • Unable to complete all study requirements in English

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Prevalence of type-specific HPV typesBaseline

The oral, penile and anal prevalence of type-specific HPV types

Prevalence of quadrivalent vaccine HPV typesBaseline

The oral, penile and anal prevalence of quadrivalent vaccine types (6, 11, 16 and 18)

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Melbourne Sexual Health Centre

🇦🇺

Melbourne, Victoria, Australia

© Copyright 2025. All Rights Reserved by MedPath